The right therapy matters.

In a subgroup analysis, 99% of patient days were attack free for up to 2.7 years1†

Photo does not depict actual patients.

* In a post-hoc analysis of 63 patients, median time to first attack in patients followed over a mean of 1.5 years in a long-term, open-label study was 223 days.2

In a subgroup analysis of 24 U.S. patients receiving 60 IU/kg of HAEGARDA eligible to continue the open-label extension study for >12 months.1

indicated for patients 6 years and older

HAEGARDA is the only HAE preventive therapy that delivers:

arrow pointing downwards with 95 percent symbol

95% reduction in HAE attacks

plus symbol
arrow pointing downwards with 99 percent symbol

>99% less rescue medication use

plus symbol
icon of C1-INH

Replacing missing or dysfunctional C1‑INH


The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.4

Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

§ Median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA vs placebo.

medical prescription symbol

Get your patients started on HAEGARDA

haegarda symbol
References: 1. Craig T, Feuersenger H, Pragst I, et al. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43:202-208. 2. Craig T, Feuersenger H, Pragst I. Durability of symptom control with long-term prophylactic therapy with subcutaneous C1-inhibitor in patients with hereditary angioedema. Presented at: 33rd Annual Eastern Allergy Conference; August 16-18, 2020; Palm Beach, FL. 3. Longhurst H, Cicardi M, Craig T. COMPACT Investigators. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140. 4. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema — the 2021 revision and update. WAO Journal. 2022;15:1-39.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

You are now leaving the current website.

Do you want to continue?